×




China Novartis Institute for Biomedical Research: Building a sustainable, globally integrated research enterprise Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for China Novartis Institute for Biomedical Research: Building a sustainable, globally integrated research enterprise case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. China Novartis Institute for Biomedical Research: Building a sustainable, globally integrated research enterprise case study is a Harvard Business School (HBR) case study written by Vicki L. Sato, Christoph Jaeker, Pooja Mehta Solanki. The China Novartis Institute for Biomedical Research: Building a sustainable, globally integrated research enterprise (referred as “Biomedical China” from here on) case study provides evaluation & decision scenario in field of Leadership & Managing People. It also touches upon business topics such as - Value proposition, Cross-cultural management, Global strategy, Internet, Strategy execution.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of China Novartis Institute for Biomedical Research: Building a sustainable, globally integrated research enterprise Case Study


To maximize their effectiveness, color cases should be printed in color.As the head of the Novartis Institute for Biomedical Research in China, En Li was shepherding a $1 billion R&D investment in China. So far he had been able to attract a large number of Chinese-born but US-trained scientists to play a critical role in establishing the site. How sustainable was this strategy, and what were the key things he had to do right to establish a globally integrated R&D unit in China?


Case Authors : Vicki L. Sato, Christoph Jaeker, Pooja Mehta Solanki

Topic : Leadership & Managing People

Related Areas : Cross-cultural management, Global strategy, Internet, Strategy execution




Calculating Net Present Value (NPV) at 6% for China Novartis Institute for Biomedical Research: Building a sustainable, globally integrated research enterprise Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10007501) -10007501 - -
Year 1 3468999 -6538502 3468999 0.9434 3272641
Year 2 3953838 -2584664 7422837 0.89 3518902
Year 3 3959436 1374772 11382273 0.8396 3324419
Year 4 3226900 4601672 14609173 0.7921 2556007
TOTAL 14609173 12671968




The Net Present Value at 6% discount rate is 2664467

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Payback Period
2. Internal Rate of Return
3. Profitability Index
4. Net Present Value

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Timing of the expected cash flows – stockholders of Biomedical China have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.
2. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Biomedical China shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.






Formula and Steps to Calculate Net Present Value (NPV) of China Novartis Institute for Biomedical Research: Building a sustainable, globally integrated research enterprise

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Leadership & Managing People Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Biomedical China often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Biomedical China needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10007501) -10007501 - -
Year 1 3468999 -6538502 3468999 0.8696 3016521
Year 2 3953838 -2584664 7422837 0.7561 2989670
Year 3 3959436 1374772 11382273 0.6575 2603393
Year 4 3226900 4601672 14609173 0.5718 1844991
TOTAL 10454574


The Net NPV after 4 years is 447073

(10454574 - 10007501 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10007501) -10007501 - -
Year 1 3468999 -6538502 3468999 0.8333 2890833
Year 2 3953838 -2584664 7422837 0.6944 2745721
Year 3 3959436 1374772 11382273 0.5787 2291340
Year 4 3226900 4601672 14609173 0.4823 1556182
TOTAL 9484076


The Net NPV after 4 years is -523425

At 20% discount rate the NPV is negative (9484076 - 10007501 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Biomedical China to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Biomedical China has a NPV value higher than Zero then finance managers at Biomedical China can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Biomedical China, then the stock price of the Biomedical China should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Biomedical China should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What will be a multi year spillover effect of various taxation regulations.

What can impact the cash flow of the project.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

Understanding of risks involved in the project.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of China Novartis Institute for Biomedical Research: Building a sustainable, globally integrated research enterprise

References & Further Readings

Vicki L. Sato, Christoph Jaeker, Pooja Mehta Solanki (2018), "China Novartis Institute for Biomedical Research: Building a sustainable, globally integrated research enterprise Harvard Business Review Case Study. Published by HBR Publications.


Codexis SWOT Analysis / TOWS Matrix

Basic Materials , Chemical Manufacturing


Pointer SWOT Analysis / TOWS Matrix

Services , Communications Services


GIR Natureview Resorts Ltd SWOT Analysis / TOWS Matrix

Capital Goods , Construction Services


Bestone com SWOT Analysis / TOWS Matrix

Services , Personal Services


Avicopter PLC SWOT Analysis / TOWS Matrix

Capital Goods , Aerospace & Defense


Asia Pacific A SWOT Analysis / TOWS Matrix

Consumer Cyclical , Auto & Truck Parts


Brisbane Broncos Ltd SWOT Analysis / TOWS Matrix

Services , Recreational Activities


Starts Publishing SWOT Analysis / TOWS Matrix

Services , Printing & Publishing


Everdigm SWOT Analysis / TOWS Matrix

Consumer Cyclical , Auto & Truck Manufacturers